TILS | Jotup

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on:

星期四, 五月 9, 2024

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points:

The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
"We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on:

星期四, 五月 9, 2024

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points:

The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
"We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on:

星期四, 五月 9, 2024

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points:

The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
"We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on:

星期四, 五月 9, 2024

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points:

The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
"We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Retrieved on:

星期四, 五月 9, 2024

SNF, FOLFIRINOX, DOI, Blood, Pancreatic cancer, Poster, TILS, Immunotherapy, TSX, PR, MD, Tumor microenvironment, AB, ONC, Roche, PDAC, Cancer, Patient, Pancreatic Cancer Action Network, AIO, Medicine, SWI, MMSc, Ethics, PD, Therapy, SAN, Anal cancer, TME, Pharmaceutical industry

SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer. The chemotherapy regimens of mFOLFIRINOX or gemcitabine + nab-paclitaxel are the two most common standards of care for pancreatic cancer.1 Oncolytics has already reported data with the combination of gemcitabine and nab-paclitaxel (link to the PR, link to the poster) that surpassed historical outcomes.2-5 Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.

Key Points:

This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC).
It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer.
"Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC.
"We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.

Epsilon Reports First Quarter 2024 Results

Retrieved on:

星期三, 五月 8, 2024

Permian, NRI, Central Time, Investment, News, Natural gas, TILS, MMBTU, Conference, Webcast, PDP, TIL, Acquisition, Interest, Cubic foot, Oil

Epsilon’s capital expenditures were $21.4 million for the quarter ended March 31, 2024.

Key Points:

Epsilon’s capital expenditures were $21.4 million for the quarter ended March 31, 2024.
In addition, our operating partner in PA curtailed production in response to low realized gas prices in the first quarter (quantified above).
The Company will host a conference call to discuss its results on Thursday, May 9, 2024 at 9:30 a.m. Central Time (10:30 a.m. Eastern Time).
Participants should ask to be joined to the “Epsilon Energy First Quarter 2024 Earnings Conference Call.”
A webcast can be viewed at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=BtayVC7k .

Civitas Resources Reports First Quarter 2024 Results

Retrieved on:

星期四, 五月 2, 2024

Oil, Gas, Energy, Permian, Acquisition, Natural gas, NGL, TIL, TILS, Civitas

As a result of operational efficiencies achieved in the Permian Basin, Civitas drilled three net miles (1.5 wells) and completed six net miles (3 wells) more than planned in the first quarter.

Key Points:

As a result of operational efficiencies achieved in the Permian Basin, Civitas drilled three net miles (1.5 wells) and completed six net miles (3 wells) more than planned in the first quarter.
“This quarter was the first reporting period that all our new businesses were together, and our results highlight just the beginning of Civitas' bright future ahead.
Sales volume for the first quarter 2024 were higher than expected at 336 MBoe/d, which benefited from continued strong well performance and accelerated turn-in-line ("TIL") timing.
NGL realizations per barrel represented 29% of West Texas Intermediate crude oil in the first quarter of 2024.

Turnstone Biologics Appoints William Waddill to its Board of Directors

Retrieved on:

星期二, 四月 16, 2024

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.

Key Points:

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.
The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors.
“I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone,” said Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer.
“Will is a highly accomplished biotechnology executive and Board member, and his impressive track record and deep operational and financial acumen make him a valuable addition to our Board.

RootPath Announces Publication Demonstrating How Its Novel Gene Synthesis Technology Empowers Cell Therapy in Solid Tumor Cancers

Retrieved on:

星期二, 四月 23, 2024

RootPath , a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced a new publication in Nature Biotechnology detailing research that demonstrates the power of the company’s novel gene synthesis technology and how it may contribute to successful cell therapy in solid tumor cancers.

Key Points:

RootPath , a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced a new publication in Nature Biotechnology detailing research that demonstrates the power of the company’s novel gene synthesis technology and how it may contribute to successful cell therapy in solid tumor cancers.
The publication is titled “ Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening ”.
With the help of RootPath’s innovative synthesis technology, we now improved the throughput of this approach by a factor of 100.
The company will soon offer TCR gene synthesis and screening services commercially, as reported in the study.

Ibex Medical Analytics Wins Edison Bronze Award for AI-Powered Breast Cancer Diagnostics Solution

Retrieved on:

星期五, 四月 19, 2024

BOSTON, April 19, 2024 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced that Galen™ Breast HER2 has been named a bronze winner of the 2024 Edison Awards in the Diagnostic Technologies category. The awards, named after inventor Thomas Alva Edison, honor companies and innovations that are shaping the future, creating a positive impact in the world and improving lives.

Key Points:

BOSTON, April 19, 2024 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced that Galen™ Breast HER2 has been named a bronze winner of the 2024 Edison Awards in the Diagnostic Technologies category.
Breast cancer impacts one in eight American women and as such, accurate and timely diagnosis is key to guiding treatment decisions and improving survival rates.
Ibex's Galen Breast HER2 is an AI-powered scoring solution that helps pathologists assess HER2 expression in tumors to support identification of breast cancer patients eligible for targeted therapies.
The award highlights our innovative approach in developing AI-powered tools such as Galen Breast HER2 that set the new standard in breast cancer diagnosis."